This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Endo (ENDP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Endo's (ENDP) fourth-quarter earnings might have gained from higher sales of Xiaflex.
Universal Health (UHS) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Universal Health Services' (UHS) fourth-quarter results are likely to reflect the benefits of improving patient volumes.
Viatris (VTRS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q4 earnings might have gained from the solid performance of Lipitor, Influvac, Viagra and EpiPen.
Avid (CDMO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Avid Bioservices (CDMO) is set to provide updates on its CDMO business and other such developments when it reports earnings results for third quarter of fiscal 2022.
What's in the Cards for Bausch Health (BHC) Q4 Earnings?
by Zacks Equity Research
An update on the IPO of Bausch+Lomb and regular top-line and bottom-line numbers will grab investors' attention when BHC reports Q4 results.
Vir Biotechnology, Inc. (VIR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Dynavax's (DVAX) Growth Momentum Continue in 2022?
by Zacks Equity Research
Year-over-year revenue growth for HEPLISAV-B and CpG 1018 adjuvant is expected to drive Dynavax???s (DVAX) profitability in 2022.
Mednax (MD) to Post Q4 Earnings: Here's What You Need to Know
by Zacks Equity Research
Mednax's (MD) fourth-quarter results are likely to reflect growth in same-unit revenues and NICU days.
ProQR (PRQR) Plunges as Lead Drug Fails in Phase II/III Study
by Zacks Equity Research
ProQR (PRQR) lead candidate sepofarsen did not meet primary and secondary goals in phase II/III study.
Gilead (GILD) Veklury Retains Activity Against Omicron Variant
by Zacks Equity Research
Gilead's (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies.
Will Patient Days Drive Community Health (CYH) Q4 Earnings?
by Zacks Equity Research
Community Health Systems' (CYH) fourth-quarter results are likely to reflect a higher occupancy rate and average length of stay.
Glaxo (GSK) Q4 Earnings Top Estimates, Xevudy Adds $1.1B in Sales
by Zacks Equity Research
Glaxo's (GSK) revenues benefit from the recovery in sales of new and specialty drugs, and Consumer Healthcare products along with additional revenues from COVID-19 drug, Xevudy.
Vir (VIR) Announces Encouraging Data on COVID-19 Antibody
by Zacks Equity Research
Vir (VIR), Glaxo's sotrovimab retains neutralizing activity against the BA.2 subvariant of Omicron, per preclinical data.
Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA
by Zacks Equity Research
Regeneron (REGN) and Sanofi get Priority Review for their sBLA in the United States seeking label expansion of Dupixent.
Amgen (AMGN) Provides Strong Long-Term Outlook, Shares Up
by Zacks Equity Research
Amgen (AMGN) outlines a strategy to grow its business through the end of this decade on the back of strong demand for existing products and potential of novel pipeline candidates targeting diverse indications.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases fourth-quarter 2021 results.
4 Drug, Biotech Stocks Set to Beat Q4 Earnings Estimates
by Ekta Bagri
Let us take a look at some drug/biotech stocks like VIR, MRNA, JAZZ and ACAD that are poised to beat on fourth-quarter earnings.
Incyte (INCY) Q4 Earnings Miss, Sales Beat on Jakafi, Royalties
by Zacks Equity Research
Incyte's (INCY) earnings miss, but revenues surpass estimates in the fourth quarter on higher royalty revenues and increased Jakafi sales.
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 157%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Vir Biotechnology, Inc. (VIR) points to a 156.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Catalyst's (CPRX) Stock Up on 2022 Guidance for Firdapse
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) reports preliminary sales figures for the fourth quarter. The company also provides its revenue guidance for 2022.
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates, especially its lead candidate CTX001.
Glaxo (GSK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven fourth-quarter sales. The performance of vaccines during Q4 remains to be seen.
Viatris (VTRS) Gets FDA Nod for Generic Drug in Dry Eye Disease
by Zacks Equity Research
Viatris' (VTRS) subsidiary is the first to receive approval from the FDA to market a generic version of AbbVie's Restasis for the treatment of dry eye disease.
Bristol-Myers (BMY) Q4 Earnings Meet Estimates, Sales Beat
by Zacks Equity Research
Bristol-Myers (BMY) earnings match estimates in the fourth quarter of 2021, while sales beat the same on the back of Eliquis and Opdivo.
Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 2.11% and 4.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?